젠프렉스(GNPX)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.45 (-0.29%), 시가총액 $8.97M, 52주 범위 $0.14 ~ $11.50.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
젠프렉스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
젠프렉스의 현재 주가는 $3.45 (-0.29%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
젠프렉스의 시가총액은 약 $8.97M입니다.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.